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Abstract
Autoimmune lymphoproliferative syndrome (ALPS) is caused by genetic defects decreasing Fas function and is
characterized by lymphadenopathy/splenomegaly and expansion of CD4/CD8 double-negative T cells. This latter
expansion is absent in the ALPS variant named Dianzani Autoimmune/lymphoproliferative Disease (DALD). In
addition to the causative mutations, the genetic background influences ALPS and DALD development. We previously
suggested a disease-modifying role for the perforin gene involved in familial hemophagocytic lymphohistiocytosis
(FHL). The UNC13D gene codes for Munc13-4, which is involved in perforin secretion and FHL development, and
thus, another candidate for a disease-modifying role in ALPS and DALD. In this work, we sequenced UNC13D in 21
ALPS and 20 DALD patients and compared these results with sequences obtained from 61 healthy subjects and 38
multiple sclerosis (MS) patients. We detected four rare missense variations in three heterozygous ALPS patients
carrying p.Cys112Ser, p.Val781Ile, and a haplotype comprising both p.Ile848Leu and p.Ala995Pro. Transfection of
the mutant cDNAs into HMC-1 cells showed that they decreased granule exocytosis, compared to the wild-type
construct. An additional rare missense variation, p.Pro271Ser, was detected in a healthy subject, but this variation
did not decrease Munc13-4 function. These data suggest that rare loss-of-function variations of UND13D are risk
factors for ALPS development.
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Introduction
The lytic granules of cytotoxic T cells (CTL) and natural killer
(NK) cells contain perforin and granzymes, which are released
on the target cell surface and induce its death[1]. . The
exocytosis mechanism of the lytic granules is not fully
understood, but it involves machinery composed of several
proteins including Munc13-4, Munc18-2, and syntaxin11 [2].
Deficiencies of perforin function are responsible for familial
hemophagocytic lymphohistiocytosis (FHL), an autosomal
recessive disease characterized by bouts of prolonged fever,
hepatosplenomegaly, and cytopenia due to defective function
of CTL and NK cells. FHL has been ascribed to defective
clearance of virus-infected cells leading to cytokine and effector
cell overproduction with massive tissue damage [3].
Approximately 40% of FHL cases (FHL2) are due to mutations
of the perforin gene (PRF1), with another 40% (FHL3) due to
mutations of the Munc13-4 gene (UNC13D). Moreover, a small
number of patients with FHL have been found to harbor
mutations of STX11, encoding Syntaxin-11 (FHL4), or
STXBP2, encoding Munc18-2 (FHL5) [4].
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Autoimmune lymphoproliferative syndrome (ALPS) is
another genetic lymphoproliferative disease and is
characterized by lymphadenomegaly and/or splenomegaly, due
to polyclonal accumulation of lymphocytes, and peripheral
expansion of CD4/CD8 double-negative (DN) T cells [5–10]. In
addition, patients often display autoimmune manifestations that
predominantly involve blood cells and are predisposed to
lymphomas in adulthood [11]. ALPS is due to defective function
of the Fas/Apo-1 (CD95) death receptor, inducing apoptosis of
the Fas-expressing cell upon binding with Fas ligand (FasL)
[12,13]. Activated lymphocytes express Fas and the Fas/FasL
interaction is involved in shutting off immune responses,
lymphocyte lifespan regulation, and maintenance of peripheral
tolerance [14,15]. Moreover, the Fas pathway is an additional
weapon, reinforcing the perforin system in the cytotoxicity
mediated by CTL and NK cells because these cells express
FasL and induce apoptosis of target cells expressing Fas. In
most patients (ALPS-FAS), ALPS is due to mutations of the
Fas gene (FAS), but a small number of patients (ALPS-FASL
and ALPS-CASP10) carry mutations in the genes encoding
FasL (FASL) or caspase-10 (CASP10), a downstream effector
in the Fas/FasL pathway. As a substantial proportion of ALPS
patients (ALPS-U) lack mutations in FAS, FASL, and CASP10;
it seems likely that mutations in unknown genes encoding other
downstream components of the Fas cell death pathway may
give rise to the additional ALPS cases [9,10]. We have also
described an incomplete form of ALPS showing defective Fas
function, autoimmunity, and lymphoproliferation, but lacking the
expansion of DN T cells. This variant form has been named
Dianzani Autoimmune Lymphoproliferative Disease (DALD) by
Victor McKusick (OMIM # 605233) [10,16–18]. Patients with
DALD did not display mutations in FAS, FASL, or CASP10, but
most of the parents displayed a defect in the Fas pathway.
These data suggest that mutations in genes encoding
downstream effectors of the Fas pathway may also give rise to
DALD.
In addition to the Fas defect, the clinical presentation of
ALPS also appears to be influenced by modifier genes. In
mice, a disease displaying features of ALPS has been reported
for MRL lpr/lpr and gld/gld mice, carrying mutations of FAS and
FASL, respectively. Disease presentation in these mice is
dramatically affected by strain background, with strains other
than MRL showing much milder phenotypes when homozygous
for either lpr or gld mutations [12,19]. Similar background
effects likely explain the incomplete penetrance of ALPS
mutations in humans [20]. Most ALPS patients are
heterozygous for the FAS mutation, but parents carrying the
same mutation are generally healthy. The same observation is
true in DALD, where parents typically display defective Fas
function, but are otherwise healthy [17,18]. This observation
indicates that mutations in genes of the Fas pathway may be
necessary but not sufficient for ALPS development and
variations in one or more additional genes may influence
disease presentation [9].
In previous works, we correlated certain variants of the
perforin gene (PRF1) with ALPS/DALD development and
suggested that mild heterozygous variations of PRF1 incapable
of inducing FHL may act as susceptibility genes for ALPS/
DALD development in subjects displaying defective Fas
function [21,22]. The aim of this work was to extend this
observation to the UNC13D gene, looking for variations in
ALPS and DALD patients and assessing its potential role as a
disease-modifier gene. We found that loss-of-function
variations of UNC13D are relatively frequent in patients with




We analyzed 41 unrelated Italian patients, 21 with ALPS and
20 with DALD. All patients were diagnosed at the Pediatric
Department of the University of Turin using criteria established
at the 2009 ALPS NIH International Workshop [10]. FAS (NCBI
ID: 355) and CASP10 (ID: 843) were sequenced in all patients
as reported previously [16,17]. Among the ALPS patients, 7
carried heterozygous mutations of FAS (ALPS-FAS), 14 did not
carry any known mutation (ALPS-U). None of the patients
fulfilled the diagnostic criteria for FHL. A total of 61 healthy
individuals were used as controls for UND13D sequencing, and
a second cohort of 100 healthy controls were used to genotype
the rare variations. Moreover, UNC13D was sequenced in 38
patients with Multiple Sclerosis (MS) from the MS Center of the
"Amedeo Avogadro" University of Eastern Piedmont (Novara).
The study was planned according to the guidelines of the local
ethical committee, Azienda Ospedaliera della Carità, of Novara
that approved the study (Protocol 106/CE). For the patients
followed at Paediatric Department of the University of Torino, a
written informed consents was signed by the patients, or by the
parents if they were minors.
Fas function assay
Fas-induced cell death was evaluated on T cells obtained by
activating peripheral blood mononuclear cells (PBMC) with
phytohemagglutinin (Sigma, St Louis, MO, Canada) at days 0
(1 µg/mL) and 12 (0.1 µg/mL) and cultured in RPMI 1640 plus
10% fetal calf serum and recombinant IL-2 (rIL-2, 2 U/mL)
(Sigma). Fas function was assessed 6 days after the second
stimulation (day 21). Cells were incubated with control medium
or anti-Fas monoclonal antibody (mAb) (CH 11, 1 µg/mL)
(Millipore, Billerica, MA) in the presence of rIL-2 (1 U/mL) to
minimize spontaneous cell death. Cell survival was evaluated
after 18 hours by counting live cells by the trypan blue
exclusion test. Assays were performed in duplicate. Cells from
2 healthy donors were included in each experiment as positive
controls. The results were expressed as percent specific cell-
survival, calculated as follows: (total live-cell count in the assay
well/total live-cell count in the control well) X100%. Fas function
was defined as defective when cell survival was less than 82%
(the 95th percentile of data obtained from 200 healthy controls)
[17,18].
UNC13D sequencing
Genomic DNA was isolated from peripheral blood samples
using a BioRobot® EZ1 Workstation (Qiagen, Jesi, Italy).
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Exons and intron-exon boundaries of UNC13D (ID: 201294),
were amplified and directly sequenced in both directions with
the BigDye® Terminator Cycle Sequencing Ready Reaction Kit
(Applied Biosystems, Foster City, CA, USA). Primers are
available upon request. Sequences were analyzed and
compared with the reported gene structure. The missense
variations identified in patients were also assessed in parents.
Allele expression was evaluated in total RNA extracted from
PBMC of heterozygous donors. RNA was reverse transcribed
into cDNA with the ThermoScriptTM RT PCR System
(Invitrogen, Burlington, ON, Canada) and the exons containing
the UND13D variations were amplified. PCR products were
subcloned into the pGEM-T vector (Promega Corporation,
Madison, WI, USA) and transformed into TOP10 E. coli
competent cells (Invitrogen). In each selected patient, we
screened 30 independent colonies; plasmid DNA was extracted
with a QIAPrep Spin miniprep Kit (QIAGEN GmbH, Hilden,
Germany) and sequenced.
Functional analysis of the variations
Munc13-4 cDNA (ImaGenes, BioDiscovery, Inc. Suite CA,
USA) was subcloned into the pcDNA 3.1 expression vector
(Invitrogen), and the Sv5 tag was added at the 5′ end by PCR.
The mutants were created in the Munc13-4 wild-type construct
by PCR and then transfected into the HMC-1 human mast cell
line, originally established from the peripheral blood of a patient
with mast cell leukemia [23] and kindly provided by C.
Dianzani. Cells were transfected by Amaxa Cell Line
Nucleofactor Kit V (Lonza, Basel, Switzerland), according to
the manufacturer’s instructions. Briefly, 4 µg of each construct
were co-transfected with 1 µg of the pEGFP vector (Invitrogen).
Transfection efficiency was analyzed by cytofluorimetric
evaluation, and determined by calculating the % of GFP
expressing cells. To investigate Munc13-4 expression levels,
cells were lysed and proteins resolved by gel electrophoresis
were analyzed using mAb to Sv5 and actin (Santa Cruz
Biotechnology, Inc. Santa Cruz, CA, USA). Immunoreactive
proteins were visualized with HRP-conjugated goat anti-mouse
IgG (Sigma).
To investigate primary granule exocytosis, transfected
HMC-1 cells (1x106/ml) were incubated in Tyrod Buffer (Hepes
10 mM pH=7.4, NaCl 173 mM, KCl 2.9 mM, NaHCO3 12 mM
with 1.6 mM CaCl2 and 5 mM Glucose) and stimulated with 10-6
M formyl-methionyl-leucyl-phenylalanine peptide (fMLP, Sigma)
at 37°C for 10 min. Exocytosis was then assessed on the GFP-
expressing cells by cytofluorimetric analysis of CD63
expression, using the mean fluorescence intensity ratio
between stimulated and unstimulated cells set at 100% [24].
The functional effects of the FAS mutations were assessed
by transfecting the mutated cDNA, subcloned into pcDNA3.1
(Invitrogen) in 293T cells. Wild-type cDNA of FAS bearing the
FLAG tag at the 5′-end was a kind gift of Giovina Ruberti
(National Research Council, CNR, Rome). The p.Gln273His
and p.Glu261Lys mutants were created in the FAS construct by
PCR. Cells were transfected and lysed as for Munc13-4 and
immunoblotted with anti-FLAG mAb (Sigma).
Analysis of caspase-8 activity
Caspase-8 activity was evaluated, as previously reported
[25], in 100 µg of cell lysates obtained from Fas-transfected
293T cells (5 x 106), 24 hours after transfection, using a
fluorimetric assay according to the manufacturer’s instructions
(MBL, Watertown, MA). The results were expressed as relative
caspase-8 activity (in %), which was calculated as (activity of
Fas transfected cells/activity of mock transfected cells) X100%.
Functional analyses of patient NK cells
PBMC were cultured overnight at 37°C in 5% CO2 in media
with or without rIL-2 (600 UI/ml) (Proleukin, Chiron Corp.,
Emeryville, USA) to test degranulation of resting and activated
NK cells, respectively. PBMC derived from patients’ relatives
and/or unrelated healthy donors were tested in parallel.
Surface expression of CD107a was assessed on CD3-CD56+
cells upon co-incubation of PBMC with K562 cells in the
presence of Phycoerythrin-conjugated anti-CD107a mAb for 2
hours at 37°C, as previously described [26,27]. Thereafter,
cells were stained with APC-conjugated anti-CD56 and PerCP-
conjugated anti-CD3 mAb, and analyzed by flow cytometry
(FACSCalibur, Becton Dickinson Biosciences, CA, USA). The
results were considered by assessing the change in % CD107a
(i.e., % CD107a+ cells in stimulated samples – % CD107a+
cells in unstimulated samples). All reagents were from BD
Biosciences. NK cells were also purified using the RosetteSep
method (StemCell Technologies, Vancouver, British Columbia,
Canada), following manufacturer’s instructions, and cultured in
appropriate conditions to obtain high numbers of polyclonal
activated NK cells [26]. To analyze the cytolytic activity in 4
hour 51Cr-release assays, PBMC were tested against K562
cells, while activated NK cells were tested against the HLA-
class I-negative B-EBV cell line 721.221, as previously
described; lytic units were calculated at 30% lysis [26,27].
Statistical analysis
Statistical analysis was performed using the ANOVA
followed by Dunnett’s multiple comparison test; *p<0.05,
**p<0.01. The results are shown as the mean and standard
error (SE). Genotype distributions were analyzed with the
Fisher’s exact test. All P-values are 2-tailed, and the
significance cut-off was p<0.05.
Results
Genetic analyses
The coding sequences (exons and intron boundaries) of
UNC13D were sequenced in 21 patients with ALPS (ALPS-
FAS: N=7; ALPS-U:N = 14) and 20 with DALD. We identified 6
heterozygous missense variations in UNC13D in 8 patients (2
ALPS-FAS, 3 ALPS-U, 3 DALD). The variations and their
inheritance are described in Table 1 and Figure 1.
Two variations had been previously described in patients
with FHL; two patients carried p.Ala59Thr (c.175G>A;
rs9904366) and three p.Arg928Cys (c.2782C>T; rs35037984).
Four other variations were identified, i.e., p.Cys112Ser (c.
335G>C; rs141540493), p.Val781Ile (c.2342G>A;
Role of UNC13D Gene in ALPS/DALD Development
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Table 1. Gene variations detected in patients with ALPS or DALD.
Patients
(gender) Diagnosis Fas function* FAS UNC13D
 Pt Pt F M Variation Inh† Variation Inh†
Pt.1 (female) ALPS-FAS D D N p.Gln273His F p.Arg928Cys M
     (c.819G>C)  (c.2782C>T) or F‡
Pt.2 (male) ALPS-FAS D ND ND p.Glu261Lys F p.Cys112Ser M
     (c.755G>A)  (c.335C>G)  
Pt.3 (female) ALPS-U D D D   p.Ala59Thr M
       (c.175G>A)  
Pt.4 (male) ALPS-U D D D   p.Ile848Leu M
       (c.2542A>C)  
       p.Ala995Pro M
       (c.2983G>C)  
Pt.5 (female) ALPS-U D ND ND   p.Val781Ile ND
       (c.2342G>A)  
Pt.6 (male) DALD D D D   p.Ala59Thr F
       (c.175G>A)  
Pt.7 (female) DALD D D D   p.Arg928Cys M
       (c.2782C>T)  
Pt.8 (male) DALD D D ND   p.Arg928Cys ND
       (c.2782C>T)  
* D = defectve, N = normal, Pt = patient, F = father, M = mother
† Inheritance, F = father, M = mother; ND = not determined; no parent displayed ALPS, DALD, XLP, or FHL; Pt.1’s mother had rheumatoid arthritis.
‡ both parents carried the variation.
Figure 1.  UNC13D and FAS variations carried by ALPS/DALD patients.  Graphical representation (not in scale) of the
Munc13-4 [A] and Fas [B] proteins (upper schemes: numbers indicate the amino acid positions) and genes (lower scheme: boxes
represent the exons; arrows indicate the mutations). C2: C2 domain; MHD: Munc13-homology domain. PLAD: preligand assembly
domain; TM: transmembrane domain; DD: death domain.
doi: 10.1371/journal.pone.0068045.g001
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rs149871493), p.Ile848Leu (c.2542A>C; rs144968313), and
p.Ala995Pro (c.2983G>C; rs138760432). These variations
have been recently described in the dbSNP database as rare
variants with an allele frequency of <0.01%, and each variant
was found in a single patient. Pt. 4 carried two variations,
p.Ile848Leu and p.Ala995Pro, inherited from the same parent.
To assess the variation frequency in the general populations
and in subjects with a different autoimmune disease, we
sequenced UNC13D in 61 healthy controls and 38 patients with
MS. The results showed that p.Ala59Thr was found in 5 healthy
controls and 3 MS patients, and p.Arg928Cys in 8 healthy
controls and 2 MS patients. Moreover, one healthy control
carried the novel variation p.Pro271Ser (c.811C>T), absent in
the other groups (Table 2). Because p.Ala59Thr and p.
Arg928Cys were detected in all patients and control groups
with similar allelic frequencies, they were not further
considered. Because p.Cys112Ser, p.Val781Ile, p.Ile848Leu,
and p.Ala995Pro were detected in the ALPS group alone, we
further assessed their frequency in the Italian population by
genotyping them in 100 additional healthy controls. None of
these variations were identified in the healthy controls,
indicating that their allele frequency is relatively low.
Of the five patients whose inheritance pattern of UNC13D
variations could be determined, four (80%) were maternal and
one (20%) was paternal (Table 1). To evaluate whether this
apparent bias was due to genetic imprinting favoring
expression of the maternal allele, we performed RT-PCR on
mRNA derived from Pt.2, Pt.7, and two other patients who
were heterozygous for the common synonymous polymorphism
c.3198A>G (p.Gln1066Gln). Complementary DNA were then
cloned, and 30 independent clones were sequenced for each
patient. The results showed that both alleles were expressed at
approximately the same levels in each subject, which did not
support maternal genetic imprinting in these patients (data not
shown).
Functional analyses
Fas-induced cell death assessed in T cells from the ALPS
and DALD patients carrying the UNC13D variations is shown in
Figure 2A. All patients displayed defective Fas function except
for Pt.1, whose Fas function was considered as borderline with
regard to statistical significance.
The FAS mutations present in Pt.1 and Pt.2 were
p.Gln273His and p.Glu261Lys missense mutations,
respectively. To assess their effect on Fas function, the wild-
type (FasWT) and mutated (FasGln273His, FasGlu261Lys) forms of Fas
cDNA were transfected into 293T cells. Twenty-four hours after
transfection, 293T cells were harvested and caspase-8 activity
was assessed in cell lysates. The results showed that
caspase-8 activation was significantly lower in the cells
transfected with FasGln273His and FasGlu261Lys than in those
transfected with FasWT (Figure 2B).
The effects of the UNC13D missense variations on
Munc13-4 protein expression and NK function were evaluated
in the PBMC of all patients. NK function was evaluated by
assessing the cytotoxic activity of resting NK cells against K562
cells and that of activated NK cells against the HLA-class I-
negative B-EBV cell line 721.221. Resting and activated NK
cells were also tested for granule exocytosis, the most
appropriate assay to detect Munc13-4 defects [28]. The results
showed that values were in the normal range for all patients
(data not shown), which was consistent with previous data on
donors carrying heterozygous mutations of UNC13D.
To further assess the functional effect of the UNC13D
variations detected in one subject only, they were inserted into
a cDNA encoding UNC13D fused to the SV5 epitope tag. The
Munc13-4wt, Munc13-4Cys112Ser, Munc13-4Val781Ile,
Munc13-4Ile848Leu, Munc13-4Ala995Pro, Munc13-4Ile848Leu/Ala995Pro, and
Munc13-4Pro271Ser constructs were transfected into the HMC-1
mastocytoma cell line. Western blot analysis showed that all
constructs were expressed at similar levels indicating that the
polymorphisms did not have a substantial effect on Munc13-4
expression (data not shown). To assess the effect of these
variations on Munc13-4 function, we evaluated the capacity of
fMLP to induce secretory granule fusion with the plasma
membrane in HMC-1 cells. Fusion was monitored by an
increase in CD63 expression on the cell surface. Figure 3
shows that fMLP increased surface expression of CD63 by
similar amounts in the cells transfected with Munc13-4wt or
Munc13-4Pro271Ser constructs. In contrast, fMLP increased CD63
expression to a significantly lower extent in cells that have
been transfected with the Munc13-4Cys112Ser, Munc13-4Val781Ile,
Munc13-4Ile848Leu, Munc13-4Ala995Pro, and Munc13-4Ile848Leu/Ala995Pro
constructs (*p<0.05).
Discussion
Munc13-4 is a member of the Munc13-like family of proteins.
It is highly expressed in CTL, NK cells, and mast cells and it is
involved in granule exocytosis. Once granules are tethered to
the plasma membrane, a priming step is required to enable
Table 2. Missense variations detected in 21 ALPS, 20
DALD, 38 MS patients, and 61 healthy controls.
 Functional effect‡ ALPS DALD Controls MS
  (N=42)* (N=40)* (N=122)* (N=76)*
Frequent variations†      
Arg928Cys Not performed 1 2 8 2
Ala59Thr Not performed 1 1 5 3
Total alleles with frequent variations 2 3 13 5
      
Private variations†      
Ile848Leu‡ Loss-of-function‡ 1 0 0 0
Ala995Pro‡ Loss-of-function‡ 1 0 0 0
Cys112Ser Loss-of-function 1 0 0 0
Val781Ile Loss-of-function 1 0 0 0
Pro271Ser Normal Function 0 0 1 0
Total alleles with loss of function 3 0 0 0
p=0.03§     
* allele numbers
† amino acid substitution
‡ carried in the same allele
§ P value vs Controls (Fisher exact test)
Role of UNC13D Gene in ALPS/DALD Development
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fusion of the granule membrane with the plasma membrane. In
this priming step, granules interact with a docking complex
composed of Munc18-2 and Syntaxin-11. Thus, Munc13-4
triggers the switch of syntaxin-11 from a closed to an open
conformation enabling fusion [29].
The present study detected six missense variations of
UNC13D in ALPS-FAS (2/7, 29%), ALPS-U (3/14, 21%), and
DALD (3/20, 15%) patients. Among them, two (p.Ala59Thr,
p.Arg928Cys) had been previously reported in FHL3, whereas
the other four (p.Cys112Ser, p.Val781Ile, p.Ile848Leu,
p.Ala995Pro) were reported in the dbSNP database as rare
variations with unknown functional and pathological
significance. Moreover, both Ile848Leu and Ala995Pro have
been described in cis in one patient with systemic Juvenile
Idiopathic Arthritis (SJIA) and patients with FHL [30].
Only p.Ala59Thr and p.Arg928Cys were found in more than
one patient, with the former carried by an ALPS-U and a DALD
patient, and the latter by an ALPS-FAS and two DALD patients.
These p.Ala59Thr and p.Arg928Cys variations were detected
in several healthy controls and MS patients with similar allelic
frequencies (p.Ala59Thr: ALPS 2.4%, DALD 2.5%, healthy
controls 4.1%, MS 4%; p.Arg928Cys: ALPS 2.4%, DALD 5%,
healthy controls 6.5%, MS 2.6%). These data argue against
substantial role for these variations in ALPS and DALD. The
p.Ala59Thr variation had been previously reported in two
families with FHL, but always in cis with a pathogenic mutation,
making it difficult to assess its contribution to pathogenesis
[31]. The p.Arg928Cys variation had been previously reported
in FHL patients and a recent genotype-phenotype study
detected it in 8 patients carrying biallelic UNC13D mutations
from 7 unrelated families [27]; yet, some of these FHL3
patients had a third missense mutation too. However, it could
be a mild variant whose effect could not be detected in the
small groups of subjects used in our study.
The other four variations were carried by three ALPS
patients and were absent in DALD and MS patients, and in the
healthy controls. The p.Cys112Ser variation was detected in an
ALPS-FAS patient who also carried a FAS mutation
(p.Gln261Lys); the FAS and the UNC13D mutations were
inherited from the father and the mother, respectively. The
p.Ile848Leu and p.Ala995Pro variations were carried by an
ALPS-U patient and were in cis, as previously reported in SIJA
and FHL [30], because both of them were inherited from the
mother. The p.Val781Ile variation was detected in an ALPS-U
patient. These variations were located within key functional
domains of Munc13-4, characterized by two C2 domains (C2A,
C2B) separated by long sequences containing two Munc13-
homology domains (MHD) [29,32–34]. C2 domains bind
calcium ions and are involved in targeting proteins to cell
membranes; MHD domains are essential for the cellular
localization of Munc13-4. The p.Cys112Ser variation was
located in the C2A domain, p.Val781Ile and p.Ile848Leu in the
Figure 2.  Defective Fas function in the ALPS and DALD patients carrying the UNC13D variations.  [A] Fas-induced cell death
in T cells from the ALPS and DALD patients carrying the UNC13D variations. Activated T cells were treated with anti-Fas mAb and
survival was assessed after 18 hours. The results are expressed as specific cell survival %. The dotted line indicates the upper limit
of the normal range calculated as the 95th percentile of data obtained from 200 healthy controls; two or more were run in each
experiment as positive controls; each patient was evaluated at least twice with the same result. [B] Fas expression and caspase-8
activity in lysates of 293T cells transfected with the wild-type (WT) or mutated form of FAS (Pt.1: p.Gln273His, Pt.2: p.Glu261Lys);
cells were lysed 24 hours after transfection. Upper panels: Western blot analysis of the transfected Fas performed using anti-FLAG
and anti-β-actin antibodies. Lower panels: fluorimetric enzyme assay for caspase-8 activity. Data are relative to those displayed by
mock-transfected cells and are expressed as the mean and SE of the results from 4 experiments performed in duplicate. *p<0.05;
**p<0.01 vs. Faswt transfected cells.
doi: 10.1371/journal.pone.0068045.g002
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MHD2 domain, and p.Ala995Pro in the C2B domain. The effect
of these variations was assessed upon transfection in the
HMC-1 mast cell line, commonly used to study granule
exocytosis, which showed that all of them significantly
decreased Munc13-4 function as detected by decreased fMLP-
induced granule exocytosis. By contrast, one further variation
(p.Pro271Ser) detected in a healthy control was located in the
C2A domain but functional analysis showed that it did not
significantly decrease Munc13-4 function.
The loss of function effects detected in the transfected cells
are in contrast with the normal NK activity detected in the
PBMC of the patients carrying the p.Cys112Ser, p.Val781Ile,
p.Ile848Leu, and p.Ala995Pro variation. This discrepancy may
be ascribed to a difference in sensitivity of the two types of
assays. The NK function assays can, in fact, detect severe
defects displayed by subjects carrying biallelic loss of function
mutations of PRF1 or UNC13D, but not the mild defect
displayed by their healthy parents carrying monoallelic
mutations. By contrast, mild defects could be detected by our
assay in HMC-1 cells in which transfection forces expression of
high levels of the Munc13-4 variants.
These data showed that rare loss of function variations of
UNC13D are observed in ALPS patients with a higher
frequency (7%) than in the healthy control (0%), DALD (0%),
and MS (0%) groups. Thus, these variations may have an
impact in the development of ALPS. Support for this hypothesis
comes from a patient who carried loss-of-function mutations in
FAS, UNC13D, and XIAP. He was not included in this study
because the genetic and clinical complexity of his picture
fulfilled the diagnostic criteria of ALPS but also shared features
of FHL and X-linked lymphoproliferative disease (Boggio E. et
al, submitted).
Defective functions of Fas and Munc13-4 might cooperate in
disrupting the ability of the immune system to shut off and
interfere with the anti-viral response. These processes involve
both Fas and NK/NKT cell function whose cytotoxicity is crucial
for the clearance of virus-infected cells and the fratricide of
activated immune cells [35]. Persistence of viral infection and
an inability to switch off the immune response may contribute
to the lymphocyte accumulation and the autoimmune reactions
displayed by ALPS patients.
These data suggest that the UNC13D variations may be
considered part of an oligogenic background, predisposing
individuals to ALPS development. This may involve genes
encoding for perforin (PRF1), osteopontin (OPN), and
Signaling Lymphocyte Activation Molecule-Associated Protein
Figure 3.  Functional effect of the “private” missense variations of UNC13D.  HMC-1 cells were transiently transfected with
wild-type (WT) UNC13D and mutated forms carrying the (p.Cys112Ser, p.Val781Ile, p.Ile848Leu, p.Ala995Pro, p. Ile848Leu/
p.Ala995Pro, and p.Pro271Ser) variations (C = untransfected cells). Twenty-four hours after transfection, cells were teated (or not)
for 10 min with fMLP, and expression of CD63 was evaluated by flow cytometry. [A] Cytofluorimetric histograms of CD63 expression
in fMLP-stimulated (black) and unstimulated (white) cells transfected with each construct; one experimental representative of six is
shown. [B] Mean and SE of the fMLP-induced expression of CD63 from six experiments; results are relative to the CD63 expression
displayed by unstimulated cells (set at 100%) in each experiment; the asterisk marks the statistically significant difference versus
cells transfected with the WT form; *p<0.05; **p<0.01 vs MUNCwt transfected cells.
doi: 10.1371/journal.pone.0068045.g003
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(SH2D1A), whose variations have been suggested to be risk
factors for ALPS or DALD development. From this perspective,
patients 1, 3, 4, 5, 6, 7, and 8 also notably carried the c.
1239A>C variation of OPN, associated with ALPS and DALD
[36]. Further, patients 2 and 8 displayed hemizygosity for the
-349T variation of SH2D1A, which has been associated with
ALPS and DALD [37]. Finally, patient 7 also carried the
p.Ala91Val variation of PRF1, which has been associated with
DALD [22].
ALPS and DALD display a similar clinical picture and share
an inherited defect of Fas function and the modifying effect
exerted by variants of OPN, PRF1, and SH2D1A. However, DN
T cell expansion is only present in ALPS, which may mark
immunopathological differences because a direct role has been
ascribed to these cells in ALPS development. This work shows
that mutations of UNC13D may also represent an immunologic
difference because they were detected in ALPS but not in
DALD patients. Moreover, the UNC13D variations were not
detected in MS patients, which suggested that they are not a
common risk factor for autoimmunity. However, a possible role
of UNC13D in development of autoimmune diseases other than
ALPS has been previously suggested in patients with SJIA
[30,38], who may also display decreased NK function [39]. By
contrast, the OPN and PRF1 variants were involved in
development of several other autoimmune diseases [40–47].
Future whole-genome or exome sequencing studies will reveal
the complex genetic scenario that may contribute to ALPS and
DALD.
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